Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 14/20 | 0.55 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917489 | 0.91 | GALR3 (0.57) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL917487 | 0.91 | GALR3 (0.57) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL5361331 | 0.83 | GALR3 (0.48) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL5361334 | 0.83 | GALR3 (0.48) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL8169792 | 0.78 | GALR3 (0.55) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL916950 | 0.77 | GALR3 (0.59) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL6906025 | 0.77 | GALR3 (0.59) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL916951 | 0.77 | GALR3 (0.59) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL916900 | 0.77 | GALR3 (0.65) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL916899 | 0.77 | GALR3 (0.65) | GALR3HTR4MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 30/4885MAPT 3040/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 17/4885MAPT 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.